UBS Initiates Coverage On Spyre Therapeutics with Buy Rating, Announces Price Target of $120

UBS analyst Alice Nettleton has initiated coverage on Spyre Therapeutics (NASDAQ: SYRE) with a Buy rating. The firm has set a price target of $120 for the company's stock.